January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
January 2025 in “SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital” PRP injections are safe and effective for alopecia areata, but steroids are still the preferred treatment.
3D-ultrasound can non-invasively detect and predict alopecia areata phases and outcomes.
5 citations
,
January 2000 in “Journal of Cutaneous Laser Therapy” Choose IPL for versatility and speed, ruby lasers for precision.
September 2023 in “Journal of The American Academy of Dermatology” The document's conclusion cannot be provided because the content is not available.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
November 1998 in “Hair transplant forum international” The document's conclusion cannot be summarized because the content is not understandable.
July 2010 in “Hair transplant forum international” The ABHRS held a test in Capri, Italy.
8 citations
,
May 1941 in “Science” Inositol helped cure hair loss around rats' eyes and improved their growth.
9 citations
,
May 2002 in “PubMed” Retinoic acid affects skin and hair health by working with specific receptors, and its absence can lead to hair loss and skin changes.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
June 2025 in “Clinical Cosmetic and Investigational Dermatology” There's an urgent need for better treatments for hair loss caused by radiation therapy.
2 citations
,
June 2025 in “Journal of Investigative Dermatology” CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.
16 citations
,
November 2009 in “Experimental dermatology” Ionizing radiation damages human hair follicles by stopping cell growth, causing cell death, disrupting color, and increasing stress and damage markers.
223 citations
,
September 2018 in “Rheumatology” JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
June 2025 in “British Journal of Dermatology” An AI device for skin cancer was successfully integrated into the NHS, improving diagnosis accuracy and service capacity.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
1 citations
,
December 2016 in “Revista română de medicină de laborator” The NIPAL4 mutation c.527C>A is common in Romanian patients with autosomal recessive congenital ichthyosis.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
12 citations
,
July 2016 in “Journal of dermatology” Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.
July 2015 in “International Society of Hair Restoration Surgery”
50 citations
,
September 2011 in “Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids” Maintaining the right amount of retinoic acid is crucial for healthy hair and skin.
A new image-based method improves accuracy in measuring hair loss in mice.
April 2023 in “Journal of Investigative Dermatology” The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
7 citations
,
March 2024 in “Skin Research and Technology” miR-200c-3p could help diagnose and treat alopecia areata.
The patch effectively promotes hair growth for alopecia areata without pain.
4 citations
,
October 2021 in “Scientific Reports” NKIRAS2 can suppress certain skin tumors but its effect on cancer varies with context and expression level.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.